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Abstract
Background: The hemagglutinin (HA) glycoprotein is the principal target of protective humoral immune responses to
influenza virus infections but such antibody responses only provide efficient protection against a narrow spectrum of HA
antigenic variants within a given virus subtype. Avian influenza viruses such as H5N1 are currently panzootic and pose a
pandemic threat. These viruses are antigenically diverse and protective strategies need to cross protect against diverse viral
clades. Furthermore, there are 16 different HA subtypes and no certainty the next pandemic will be caused by an H5
subtype, thus it is important to develop prophylactic and therapeutic interventions that provide heterosubtypic protection.
Methods and Findings: Here we describe a panel of 13 monoclonal antibodies (mAbs) recovered from combinatorial
display libraries that were constructed from human IgM+ memory B cells of recent (seasonal) influenza vaccinees. The mAbs
have broad heterosubtypic neutralizing activity against antigenically diverse H1, H2, H5, H6, H8 and H9 influenza subtypes.
Restriction to variable heavy chain gene IGHV1-69 in the high affinity mAb panel was associated with binding to a
conserved hydrophobic pocket in the stem domain of HA. The most potent antibody (CR6261) was protective in mice when
given before and after lethal H5N1 or H1N1 challenge.
Conclusions: The human monoclonal CR6261 described in this study could be developed for use as a broad spectrum agent
for prophylaxis or treatment of human or avian influenza infections without prior strain characterization. Moreover, the
CR6261 epitope could be applied in targeted vaccine strategies or in the design of novel antivirals. Finally our approach of
screening the IgM+ memory repertoire could be applied to identify conserved and functionally relevant targets on other
rapidly evolving pathogens.
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Introduction
Influenza pandemics have historically been associated with high
levels of morbidity and mortality. Pandemics return periodically
and a new pandemic is now overdue. The most serious pandemic
threat in recent times has been posed by the highly pathogenic
avian influenza virus (HPAI) H5N1 which emerged in South-East
Asia in 1997 [1]. Cumulatively 385 cases have been reported with
an overall mortality of 63% [2]. In addition other avian influenza
viruses including H2, H6, H7 and H9 subtypes have been
reported to either have caused human cases or shown potential to
do so, and are also recognised as potential pandemic threats [3–6].
Preparedness to confront an influenza pandemic is still a major
public health issue. Broad spectrum antivirals, such as the
neuraminidase inhibitor oseltamivir, have been stockpiled as a
first line defence against rapidly spreading HPAI strains. However
the use of oseltamivir in the treatment of H5N1 infections has been
associated with the generation of resistant viruses [7,8] and a sharp
increase in the isolation of human H1N1 strains resistant to
oseltamivir was recorded in 2008 [9] indicating that other
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preventative measures are required. Pre-pandemic vaccination has
been put forward as a strategy to ameliorate the spread of virus
and severity of disease, however all vaccines have the limitation
that they protect at best against strains from the same subtype
[10]. Thus, an immunological intervention that will be active
across the spectrum of potential pandemic subtypes and clades
remains an elusive goal for influenza prophylaxis and therapy.
Passive immunization has been anecdotally reported to be effective
against H1N1 and H5N1 viruses [11,12], indicating that immuno-
globulins might be effective against infection and disease of the
systemic nature seen in the H1N1 1918 influenza pandemic. Based
on this, broadly cross-neutralizing monoclonal antibodies (mAbs)
against the avian influenza virus H5N1 have been pursued using a
variety of approaches [13,14]. These approaches have concentrated
on using convalescent patient material as a source of B cells for
screening of antibodies. However it has long been known that the
immune response against influenza virus is highly restricted [15], as
borne out by a recent cloning study [16], and focused on subtype and
strain specific epitopes [17,18]. Thus to access a more diverse
immune repertoire we chose the novel strategy of interrogating the
human IgM+ memory B cell repertoire. Although this subset of B cells
is characterised by CD27 expression and mutated V genes, both
tightly linked to the memory B cell phenotype, the origin and role of
this subset of B cells is controversial. It has been proposed that
circulating B cells with this phenotype are linked to marginal zone B
cells and have a primary role in T independent immunity [19,20],
while others argue they are formed as part of an intermediate
differentiation step in normal T dependent germinal centre immune
responses [21]. Several reports have highlighted a role for IgM in the
early stages of protection from experimental influenza virus challenge
[22,23]. Intriguingly this protective role includes influenza virus
subtypes to which mice are immunologically naı¨ve [23,24].
Based on our hypothesis that the IgM+ B cell subset contains a
diverse repertoire of antibodies against conserved epitopes on
pathogens we have applied antibody phage display to search for
broadly neutralizing H5N1 mAbs using combinatorial libraries
built from B cells isolated from donors recently vaccinated with the
seasonal influenza vaccine. Using this approach we have rescued a
panel of human antibodies that show an unexpected breadth of
influenza subtype neutralization that include H5, H1, H2, H6, H8
and H9 (H2, H5, H6, H9 being identified as high risk pandemic
candidates). The binding region of these mAbs has been localised
Figure 1. Construction of IgM+ memory B cell libraries. a) Donor lymphocytes were isolated by Ficoll-plaque from heparinized blood and
stained for the phenotypic markers CD27, CD24 and IgM. CD24+ CD27+ cells were gated and the IgM+ cells within this gate sorted directly into Trizol
for RNA extraction. b) RT-PCR was performed using a pool of 59 oligonucleotide primers that cover all VH gene families and a 39 oligonucleotide
primer that anneals in a region of the CH1 domain of Cm distinct from other immunoglobulin isotypes. c) Using cDNA generated in this way, 10
individual scFv libraries were constructed as described previously [26]. Donors 1020, 1030 and 1050 had been vaccinated with the Dutch 2005
seasonal influenza vaccine 7 days prior to collection of blood. All libraries demonstrated a high percentage of correct scFv ORF’s and diversity based
on unique HCDR3 sequence.
doi:10.1371/journal.pone.0003942.g001
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to a conserved region of the HA stem domain. The lead mAb
CR6261 showed prophylactic and therapeutic efficacy in mouse
models with H5N1 or H1N1 challenge.
Materials and Methods
Viruses and recombinant proteins
The reverse genetics reassortants (RG) NIBRG-14 (A/Puerto
Rico/8/34 with low pathogenic (LP) HA and NA of A/Vietnam/
1194/04; H5N1) and RG-A/Indonesia/5/05 (A/Puerto Rico/8/34
with (LP) HA and NA of A/Indonesia/5/05; H5N1) were grown in
MDCK cells by standard viral culture techniques. The wild type
H5N1 strain A/HongKong/156/97 was originally obtained from a
3-year-old child suffering from respiratory disease [25]. The virus was
passaged twice on MDCK cells. The batch (8.1 log TCID50 /ml)
used to infect mice was propagated once in embryonated eggs. A/
Vietnam/1194/04 (H5), A/Vietnam/1203/04 (H5), A/Indonesia/
5/05 (H5), A/Bar headed goose/Qinghai/5/05 (H5), A/Japanese
White Eye/Hong Kong/1038/06 (H5), A/HongKong/483/97
(H5), A/Hong Kong/54/98 (H1), A/Hong Kong/201345/07
(H1), A/Singapore/1/57 (H2), A/WF/Hong Kong/MPU3156/05
(H2), A/WF/Hong Kong/MPA2290/06 (H3), A/WF/Hong
Kong/MP2437/04 (H6), A/WF/HongKong/MPB127/05 (H7),
A/WF/HongKong/MPD373/07 (H8), A/Duck/Y280/97 (H9)
were grow in eggs or MDCK cells by standard viral culture
techniques. BPL inactivated NIBRG-14 and A/New Caledonia/20/
99 were purchased from NIBSC (UK). To generate mammalian
expressed soluble recombinant (r) HA, the coding region for A/
Vietnam/1194/04 HA excluding the transmembrane region was
synthesized and cloned in a pcDNA-based expression vector
containing a myc- and his-tag. PER.C6H cells were transfected with
the soluble HA expression constructs and rHA was purified from
culture supernatant using HisTrapTM FF Columns (GE Healthcare).
rHA, subtype H1 (A/New Caledonia/20/99), subtype H3 (A/
Wyoming/3/03), subtype H5 (A/Vietnam/1203/04), subtype H7
(A/Netherlands/219/03), subtype H9 (A/Hong Kong/1073/99)
and B/Ohio produced using baculovirus vectors in insect cells was
purchased from Protein Sciences Corp., (CT, USA).
Library construction
IgM+ memory B cells (CD24+/CD27+/IgM+) were sorted from
peripheral blood mononuclear cells obtained with written consent
from ten normal healthy donors by fluorescent activated cell
sorting (FACS, Digital Vantage, Becton Dickinson). ScFv phage
display libraries were constructed essentially as described [26]
using , 16105 sorted IgM memory B cells from each individual
donor (Supplementary Fig. 1). To ensure amplification of the IgM
memory B cell VH repertoire, an IgM-specific constant region
primer was used for the first amplification. The individual libraries
of 10 donors were rescued, amplified using CT helper phages [27]
and mixed. The pooled libraries used for phage antibody
selections consisted of more than 26108 individual clones.
Selection of HA binding clones
Phage panning to soluble rHA and (anti-Myc-captured) soluble
rHA (5.0 mg/ml in PBS, pH 7.4) immobilized to MaxisorpTM
Immunotubes (Nunc) was performed essentially as described [26],
except for the use of 100 mM TEA (Sigma) for phage elution.
Alternatively, phage selections were performed in suspension on
PER.C6H cells transfected with full length A/Vietnam/1194/04
HA or a consensus HA sequence representing H5N1 strains
isolated in Indonesia and China during 2005 as previously
described [26]. Rescue and propagation of eluted phages was
performed as described. After two rounds of selections, individual
Table 1. Sequence Characteristics of H5N1 specific scFv
No ID Clones IGHV IGHD/ frame IGHJ
VH
Mutations/
100bp
1 6364 1 1-02 1-01 / 1 4 3.8
2 6366 1 1-02 5-05 / 3 4 4.2
3 6347 2 1-02 7-27 / 3 3 2.1
4 6141 11 1-18 6-06 / 1 6 7.6
5 6365 1 1-69 1-26 / 3 3 0.7
6 6269 8 1-69 1-26 / 3 1 5.9
7 6325 1 1-69 1-26 / 3 6 4.5
8 6334 1 1-69 2/OR15-2a / 1 6 10.8
9 6261 42 1-69 2-02 / 1 6 6.9
10 6332 1 1-69 2-15 / 2 6 8.0
11 6327 1 1-69 3-03 / 2 4 5.2
12 6339 1 1-69 3-03 / 2 4 5.9
13 6344 1 1-69 3-10 / 2 4 6.6
14 6342 1 1-69 3-10 / 2 5 19.1
15 6323 18 1-69 3-22 / 2 1 5.9
16 6343 1 1-69 3-22 / 2 4 6.3
17 6331 1 1-69 3-22 / 2 5 2.8
18 6262 6 1-69 4-04 / 2 6 9.4
19 6329 1 1-69 6-25 / 1 4 9.4
20 6143 1 3-07 3-16 / 3 1 4.2
21 6151 3 3-09 5-05 / 3 4 2.8
22 6307 1 3-21 1-26 / 3 4 1.4
23 5111 31 3-21 2-08 / 2 4 3.8
24 6295 2 3-21 3-10 / 2 4 0.7
25 6302 1 3-23 1-26 / 3 4 6.3
26 6134 1 3-23 3-03 / 2 5 6.3
27 6139 7 3-23 3-10 / 2 4 5.6
28 6144 9 3-23 4-17 / 3 4 3.8
29 6301 1 3-23 5-24 / 3 5 4.2
30 6367 1 3-23 6-06 / 1 4 1.4
31 6368 7 3-23 6-13 / 2 3 3.5
32 6369 9 3-23 6-19 / 3 4 14.6
33 6299 1 3-48 3-09 / 2 4 6.3
34 6149 5 3-48 5-12 / 1 4 3.8
35 6304 1 3-48 7-27 / 1 2 9.8
36 6300 1 4-34 3-03 / 2 6 0.4
37 6148 1 4-34 4-17 / 3 4 4.6
38 6145 4 4-34 5-05 / 3 6 1.8
39 6137 29 4-39 3-10 / 3 6 3.8
40 6136 2 4-59 5-24 / 3 5 9.1
41 6132 3 5-51 4-17 / 2 6 1.7
42 6133 1 5-51 4-23 / 2 5 2.1
43 6357 1 5-51 5-24 / 3 5 1.7
Clones represent scFv with the same V(D)J recombination that were either
identical, carried mutations in the VH gene or paired with a different VL gene
compared to the prototype scFv. The table is sorted on V, D and J gene families
consecutively. The average nucleotide mutation frequency of each VH gene is
shown.
doi:10.1371/journal.pone.0003942.t001
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scFv-phage antibodies were rescued and tested for binding to rHA
and rHA-expressing PER.C6H cells in ELISA and FACS,
respectively as previously described [26].
IgG1 and Fab expression
Fully human IgG1 antibodies were constructed by cloning the
heavy (VH) and light (VL) chain variable regions of H5 rHA-specific
scFv-phage antibodies into separate vectors for IgG1 heavy and
light chain expression. Human IgG1 mAbs were expressed and
purified as described previously [28]. Fab expression constructs
were generated by recloning the VH region into a vector containing
the CH1 region of IgG1 and a myc- and his-tag. HEK293T/17 cells
were transfected with the Fab expression construct and the light
chain construct and expressed Fabs purified from culture
supernatant using HisTrapTM FF Columns (GE Healthcare).
ELISA binding assays
Microtiter plates (ImmunoTM Maxisorp, Nunc) were coated
overnight at 4uC with 0.5 mg/ml soluble rHA or BPL inactivated
virus then washed three times with PBS containing 0.1% v/v Tween-
20 and blocked in PBS containing 2% w/v non-fat dry milk (blocking
solution) for 1 hr at RT. For scFv-phage binding assays, scFv-phage
antibodies were pre-incubated for 1 hr in an equal volume of PBS
containing 4% w/v non-fat dry milk and added to the wells. After 1
hr plates were washed with PBS/0.1% v/v Tween-20 and bound
phage antibodies were detected using a peroxidase-conjugated anti-
M13 antibody (GE Healthcare). For IgG1 binding assays, anti-HA
IgG1 in blocking solution were added to wells and incubated for 1
hour at room temperature, after which bound IgG1 was detected
using a peroxidase-conjugated mouse anti-human IgG antibody
(Jackson). The reaction was developed with O-phenylenediamine
substrate (Sigma FAST OPD; Sigma) and stopped by the addition of
1M H2SO4. The absorbance was measured at 492 nm. For
competition assays, anti-HA IgG1 were incubated as above and
after washing incubated with FITC conjugated CR6261 or CR6323
(0.2 ug/ml) for 5 min at RT followed by anti-FITC rabbit IgG HRP;
detection was as above.
FACS binding assays
For scFv-phage binding assays, PEG/NaCl precipitated scFv-
phages were mixed with an equal volume of PBS/2% ELK and
blocked for 30 minutes on ice. The blocked phages were added to
pelleted cells (untransfected PER.C6H and HA-expressing PER.C6H
cells) and incubated for one hour on ice. The cells were washed three
times with PBS/1% BSA, followed by a 1 minute centrifugation at
3006g. Binding of the single chain phage antibodies to the cells was
visualized using a biotinylated anti-M13 antibody (Fitzgerald)
followed by streptavidin-phycoerythrin conjugate (Caltag). For
IgG1 binding assays, 36105 cells were incubated for 1 h on ice in
the presence of serial dilutions of anti-HA IgG1. Cells were washed
three times then incubated for 30 min with phycoerythrin-conjugated
anti-IgG (Southern Biotech). Stained cells were analyzed using a
FACS Calibur with CELLQuest Pro software (Becton Dickinson). To
assay for HA2 specific reactivity cells were treated with 10 mg/ml
trypsin-EDTA in DMEM for 30 min at RT, washed and incubated
for 5 min in acidified PBS (pH 4.9), washed and then incubated for
20 min in the presence of 20 mM DTT at RT. Cells were split at
Figure 2. Sequence analysis of VH genes from selected anti-H5 HA scFv. (a) Alignment of VH amino acid sequences from scFv containing
the same V(D)J rearrangement as CR6323 or CR6261 with the germline IGHV1-69. Note that although multiple mutations are present in the CDR1 and
CDR2 loops Phe at position 54 is conserved (Kabat numbering). scFv that were neutralizing in an IgG1 format are shown in bold (b) DNA alignment
and amino acids for the HCDR2 of (b) CR6323 and (c) CR6261 with related mAbs. Note the identical codon usage and conservation of silent mutations
suggesting a clonal origin.
doi:10.1371/journal.pone.0003942.g002
Table 2. Characteristics of the neutralizing mAb panel.
IgG1 Clones IGHV
Neutralizing activity
NIBRG-14 (mg/ml) HAI (mg/ml)
H5 competition ELISA % binding to
HA
IC100 IC50 IC50 CR6261-FITC CR6323-FITC
CR6261 23 1-69 0.78 0.55 .50 6 2
CR6329 1 1-69 3.1 1.9 .50 21 3
CR6342 1 1-69 6.3 2.19 .50 12 9
CR6325 2 1-69 6.3 2.6 .50 12 2
CR6327 1 1-69 6.3 2.6 .50 24 12
CR6323 18 1-69 6.3 3.7 .50 2 -6
CR6332 1 1-69 13 4.5 .50 9 -5
CR6334 1 1-69 6.3 4.5 .50 15 6
CR6344 1 1-69 25 6.3 .50 17 8
CR6307 1 3-21 25 8.9 .50 60 79
CR6331 1 1-69 25 10 .50 5 -3
CR6343 1 1-69 50 13 .50 52 56
CR6262 3 1-69 25 15 .50 47 44
CR5111 8 3-21 .100 .100 .50 86 113
Neg. Ctrl NA 1-69 .100 .100 .50 100 108
Hemagglutination inhibition (HAI) and microneutralizing assay are described in the methods. Competition ELISA measures the % binding of labelled CR6261 or CR6323
to H5 rHA after pre-incubation with saturating concentrations of unlabelled IgG1.
doi:10.1371/journal.pone.0003942.t002
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each step and untreated adherent cells were resuspended in 0.05%
EDTA. Cells were stained with IgG1 as described above.
Western Blotting
rHA antigen (0.4 mg/lane) was subjected to SDS-PAGE under
reducing conditions alongside the marker Precision Plus (Biorad).
Fractionated protein was transferred to Immobulon-P membrane
(Millipore), blocked with 4% milk powder and probed with 10 mg/
ml anti-H5 IgG1 containing supernatants. Immunoreactivity was
detected by chemiluminescence following incubation with a
peroxidase-conjugated mouse anti-human IgG antibody (Southern
Biotech) and 2 min ECL incubation. Membranes were exposed to
film (Hyperfilm, GE Healthcare) and image developed.
SPR analysis of Fabs
Surface plasmon resonance (SPR) analysis was performed on a
BIAcore3000. Sheep anti-NIBRIG-14 serum or FLU mAb IgG
was immobilized on a CM5 sensor chip by amine coupling and
then used to capture soluble rHA; one channel on each chip was
not coated and used as a negative control. Twelve concentrations
of Fabs in 2-fold dilutions from 1000 nM down to 0.39 nM were
injected at a constant flow rate of 100 ml/min at 25uC. At the end
of the injection, running buffer (HBS-EP, pH 7.4) was applied for
770 s, followed by regeneration of the CM5 chip using 5 ml
10 mM NaOH. The experiments were repeated twice. The
resulting data were fitted using a standard 1:1 Langmuir model
and the dissociation constant KD calculated. BIAcore evaluation
software (version 3.2, July 2001) was used throughout.
Microneutralisation assays
MDCK cells were maintained in minimum essential medium
(MEM) supplemented with 10 % fetal calf serum (FCS) and 1%
penicillin-streptomycin (PS) at 37uC. On the day of the
experiment, MDCK cells in 96-well format were washed twice
with PBS and incubated in MEM supplemented with 1% FCS,
1% PS and 1 mg/ml TPCK trypsin (for non-H5 viruses). Two-fold
serially diluted purified IgG1 or IgG1 containing supernatant was
mixed with an equal volume of viral inoculum, followed by 2 hour
incubation at 37uC. After the incubation, the mixture (,100
TCID50) was added to confluent MDCK monolayers. Cells were
cultured for 72 hours before the examination of cytopathic effect
(CPE). CPE was compared to the positive control (virus-inoculated
cells) and negative controls (mock-inoculated cells). The absence of
CPE in individual wells was defined as protection. The assay was
performed in quadruplicate.
Hemagglutination inhibition assay
Virus was diluted to 8 HA units and combined with an equal
volume of serially diluted IgG1 and incubated for 1 hr at room
temperature. An equal volume of 0.5% Turkey red blood cells was
added to the wells and incubation continued on a gently rocking
plate for 30 min. Button formation was scored as evidence of
hemagglutination.
Generation and Characterizations of Neutralization
Resistant variants
RG-A/Indonesia/5/05 was cultured in the presence of purified
CR6261 for 10 passages. A control experiment without CR6261
was done in parallel as a reference. Serially diluted (1021 to 1026
folds) viruses were first incubated in the presence of antibody (2.5
mg/ml) for 1 hour at 37uC. This concentration of antibody was
previously shown to reduce the H5N1 viral titre by 3 logs (data not
shown). The incubated mixture was then absorbed by MDCK
cells for 1 hour. Infected cells were washed with PBS twice and
replenished with MEM containing 1% FCS and 1% PS, 2.5 mg/
ml of CR6261. CPE of these infected cells was monitored 48–72
hrs post-infection. Supernatant from CPE positive wells infected
with the lowest virus titre were harvested for a subsequent round of
infection. Supernatants from passage 10 were subjected to
standard plaque assays and infected cells were overlaid with agar
containing CR6261 (2.5 mg/ml). Six individual virus plaques were
purified and grown in MDCK cells in the presence of CR6261 (2.5
mg/ml). The HA sequences of these were examined by routine
sequencing techniques. Representative mutants were character-
ized by the neutralization assays as described above.
Murine lethal challenge models
All experiments were approved prior to commencement by the
ethical review committee of the Animal Sciences Group in
accordance with Dutch law. Female 7-week-old BALB/c mice were
inoculated intranasally on the day indicated with 25 LD50 A/
HongKong/156/97 (4.5logTCID50) or A/WSN/33 (6.6logTCID50)
or , 10 LD50 A/Vietnam/1194/04 (3.7logTCID50) and observed
daily for clinical signs and weighed. Clinical signs were scored with a
scoring system (0 = no clinical signs; 1 = rough coat; 2 = rough coat,
less reactive, passive during handling; 3 = rough coat, rolled up,
laboured breathing, passive during handling; 4 = rough coat, rolled
up, laboured breathing, unresponsive) and recorded. Surviving
animals were euthanized and bled on day 21. IgG1 was injected
i.p. in a volume of 500 ml or i.v. in the tail vein in a volume of 200 ml.
Homology Modeling and Docking
Antibody modelling was performed by individually selecting
optimal framework and CDR template fragments from crystal
structures based on sequence analysis. CDR’s were grafted by
structural fit, substituted side-chains were optimised by FASTER
algorithm [29] and conjugate gradient minimization. The
Figure 3. Cross-clade H5N1 neutralizing activity and HA
subunit localization. (a) Neutralizing activity of purified IgG1 against
100 TCID50 of H5N1 viruses, the 50% neutralizing concentration (IC50)
was calculated by the Spearman-Karber method. (b) Immunoblot of H5
rHA probed with indicated IgG1. Molecular weight marker (MW) and
subunit locations indicated.
doi:10.1371/journal.pone.0003942.g003
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antibody model was then manually docked on the HA crystal
structure using the Brugel software.
PCR amplification of neutralizing mAb VH genes from
IgM+ memory B cell library cDNA
Library cDNA (200ng) was amplified with the following primer sets
sc06261_Fw (59AGGCCCCTTCCGCAGCTATGCTAT) and
sc06261_Rv_v3(59TTTCGCGCACCTGGTACCCCATATG)
CR6323_L (59AGGCACCTTCTCCAGCTATG) and
CR6323_R (59GGGGAGGTATGCAGGGTAAT)
CR6325_L (59GGAGGCACCTTCAGCTTCTA) and
CR6325_R (59GTAGTAGATACCCTTATCACCCTCTC)
CR6329_L (59GGAGGCATCTTCAGAAGCAA) and
CR6329_R (59CAAAGTAGTTGCGTGTGGTGT)
PCR reactions were performed using PWO polymerase
(Roche) and products loaded on 1,5% AGAROSE-TAE gel
Figure 4. PCR screen of individual donor libraries for neutralizing mAbs and donor serology. (a) PCR amplification of cDNA from each
donor IgM+ memory B cell library using oligonucleotide pairs designed so their 39 ends specifically anneal in the HCDR1 and HCDR3 regions. Donors
are indicated at the top of the figure. The expected size of the amplified fragment is indicated with an arrow. The identity of the bands was confirmed
by sequencing (b) Binding and neutralizing activity of donor serum collected at the same time as the B cells used for library construction (note serum
was not available for donor 12). IgM and IgG ELISA reactivity was measured against rHA and neutralizing activity against H1N1 (A/Hong Kong/54/98)
and H5N1 (A/Vietnam/1203/04). Donor 1020 who was PCR positive for the tested neutralizing mAbs is indicated in bold.
doi:10.1371/journal.pone.0003942.g004
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and detected with SybrSafe (Invitrogen). PCR products with the
expected amplicon size were extracted from gel and purified
(Zymoclean Gel DNA recovery kit, Baseclear) and cloned into
pCR4-TOPO (Invitrogen). Multiple .10 clones were sequenced
using standard techniques with the primers M13_Fw and
M13_rev.
Figure 5. Heterosubtypic binding and neutralizing activity. (a) The binding activity of the IgG1 panel (5 mg/ml) was measured against 0.5 mg/
ml directly coated recombinant HA antigen (see methods for strain designation), BPL inactivated NIBRG-14 (HA from A/Vietnam/1194/04) or BPL
inactivated H1N1 (A/New Caledonia/1/99). Detection was performed with mouse anti-human IgG-HRP and results given as OD492 nm. Control
antigens were Influenza B virus (B/Ohio/1/05) and Rabies vaccine (RIVM, Bilthoven). Anti-rabies virus (RV) IgG1 (IGHV1-69) was used as a negative
control. ELISA values.106background or between 106and 36background are coloured red and yellow respectively. (b) Phylogenetic tree of amino
acid sequences at the subtype level, division of subtypes by group is indicated by coloured balloons (blue H1 and H9, green H3 and H7). (c)
Neutralizing activity of purified IgG1 against 100 TCID50 of influenza A viruses, IC50 calculated as in Fig. 3.
doi:10.1371/journal.pone.0003942.g005
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Results
Isolation and characterization of H5N1 specific mAbs
Ten individual phage antibody libraries were constructed from
sorted IgM+ memory B cells of three donors vaccinated with a
seasonal influenza vaccine and seven unvaccinated donors (Fig. 1).
The libraries were pooled and then used for panning against
soluble or surface expressed forms of H5 recombinant (r)
hemagglutinin (HA). A total of 223 H5 rHA-specific scFv-phages
were isolated. Sequence analysis identified 91 distinct VH genes of
which 43 could be traced to a unique V(D)J recombination event
that included VH gene families 1,3,4 and 5 (Table 1). All VH
genes showed evidence of somatic mutation with an average
frequency of 5.3/100 bp, consistent with a previous analysis in this
B cell compartment [20]. We also noted that many of the mAbs
grouped in terms of V(D)J rearrangement showed signs of clonal
expansion based on conserved codon usage (Fig. 2).
Next we converted all 91 distinct scFv into full length IgG1 and
characterised them based on binding and neutralization activity. A
group of 55 clones represented by 13 mAbs with a unique V(D)J
recombination were characterised by strong binding to different
H5 rHA antigenic formats (data not shown) and in vitro
neutralizing activity (Table 2). The most potent neutralizing
mAb was CR6261, which demonstrated broad neutralizing
activity against a panel of antigenically diverse H5N1 viruses
isolated over the last decade (Fig. 3a). The neutralizing potency
range (0.6–3.7 mg/ml) of CR6261 is similar to previously reported
H5N1 neutralizing monoclonals (0.07–7 mg/ml) isolated from
immortalized B cells of H5N1 survivors [14]. However surpris-
ingly, neither CR6261 nor the other neutralizing mAbs exhibited
hemagglutination inhibition activity which is typically associated
with neutralizing activity [30] (Table 2). Western blot analysis of
the mAb panel partially explained this result by identifying two
unique neutralizing mAbs (CR6307 and CR6323) that bound to
the HA2 subunit of HA (Fig. 3b), a membrane proximal region
spatially distinct from the receptor binding domain in HA1
responsible for hemagglutination [31]. Other non-neutralizing
mAbs also showed binding to HA2 (data not shown) but only one
Table 3. Monovalent affinity of Fabs measured by surface
plasmon resonance against rHA.
mAb HA Ka (1/Ms) Kd (1/s) KD (M)
CR6261 H1 9.86105 3.761023 3.861029
H5 2.76105 1.161023 4.161029
H9 6.86105 3.761023 5.461029
CR6323 H1 1.46105 5.461024 3.961029
H5 1.96105 1.261023 6.361029
H9 1.36106 2.761023 2.161029
CR6307 H5 7.06104 4.561024 6.461029
doi:10.1371/journal.pone.0003942.t003
Figure 6. Identification of the antigenic region of neutralizing mAbs. (a) FACS binding of IgG1 to surface expressed H5 rHA was measured
after sequential treatment with trypsin (solid bars), pH 4.9 buffered medium (open bars) and DTT (striped bars) and expressed as percentage binding
to untreated rHA from two independent experiments (mean6s.e.m.). (b) Global view of CR6261, VL is rose, VH is blue, HCDR2 is green, Thr56 red and
Phe54 green. (c) Surface representation of trimeric H1 HA (A/South Carolina/1/18; 1RUZ). HA1 subunits are green, burgundy and pink, HA2 subunits
yellow, blue and orange. The hydrophobic pocket is white and shown magnified as an inset with the HCDR2 of CR6261 in green docked to the
structure. HA residues around and forming the hydrophobic pocket are labelled in black and HCDR2 residues in the pocket are green. (d)
perpendicular view of the hydrophobic pocket down the axis of helix 38–55 occupied by Phe54 of HCDR2 in purple.
doi:10.1371/journal.pone.0003942.g006
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non-neutralizing mAb (CR5111) was shown to bind the HA1
subunit (Fig. 3b; Table 2). Competition ELISA showed that 10/13
neutralizing mAbs, including CR6261, that were negative in the
western blot analysis, completely blocked binding of labelled
CR6323 to H5 rHA (Table 2) suggesting they recognise the same
antigenic region in HA2. Conversely, CR6307 which was mapped
to HA2 (Fig. 3b) only weakly inhibited CR6323 (Table 2).
Identification of donor library yielding H5N1 neutralizing
mAbs
Because the IgM+ memory B cell libraries were pooled before
selection it was not possible to immediately determine if the
neutralizing mAbs were rescued from B cells of a single donor or
different donors; we addressed this issue in two ways. Analysis of
individual IgM+ memory B cell libraries by specific RT-PCR and
sequencing showed one of the three seasonal influenza vaccinated
donors (#1020) was the source of at least 4 of the neutralizing
mAbs (Fig. 4a). This was confirmed by the isolation of scFv with
sequences identical to CR6261 in repeated selections with the
single library constructed from this donor (data not shown).
Remarkably, serum anti-H5 binding and H5N1 neutralizing titres
for donor #1020 were no different to the other vaccinated or the
unvaccinated donors (Fig. 4b) indicating that if H1N1/H5N1
cross-reactive IgM+ memory B cells were present in donor #1020
at the time of vaccination they did not mount a conventional
amnestic response and represent a small fraction of the overall
H1N1 response.
Breadth of heterosubtypic influenza virus neutralization
by the H5N1 human mAb panel
Given the conserved nature of the HA2 subunit and its known
ability to induce cross-reactive immune responses [32] we
examined whether the H5N1 neutralizing mAbs in the panel
had heterosubtypic activity. In solid phase ELISA all mAbs
recognising the antigenic region of CR6323 and CR6261
demonstrated equivalent strong reactivity to rH1, rH5 and rH9
but not rH3, rH7 or rHA from a B virus (Fig. 5a). To exclude the
possibility that the antibodies cross-reactive properties extended to
autoreactivity as has been described for several broadly neutral-
izing HIV mAbs [33] they were screened by immunohistochem-
istry on a panel of 32 human tissues. No evidence of strong specific
immunoreactivity was observed in any tissue when compared with
isotype matched control antibody (data not shown).
The monovalent affinity of CR6261, CR6323 and CR6307 was
measured by Biacore. The affinity of CR6261 and CR6323 was
similar for rH1, rH5 and rH9 HA and in the low nanomolar range
Figure 7. The hydrophobic pocket region in the stem domain of different HA subtypes. Surface representation of the hydrophobic pocket
recognized by CR6261 from crystal structures of H5 (2IBX) and H9 (1JSD) and the corresponding region from crystal structures of H3 (1MQM) and H7
(1TI8). HA residues around and forming the hydrophobic pocket are indicated in black, H3 numbering is used throughout for consistency. Note the
H38N and Q40T replacements in the H3 and H7 structures that introduce a potential glycosylation site in the region.
doi:10.1371/journal.pone.0003942.g007
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(Table 3), however while the affinity of CR6307 is high for rH5 it
recognises a different antigenic region in HA2 that is not conserved
in other influenza subtypes (Fig. 5a). To determine the full breadth
of CR6261 and CR6323 heterosubtypic neutralizing activity,
representative strains from 9 subtypes were compared. Phylogenetic
analysis based on published methodology [34] demonstrates a
subdivision of HA’s, consistent with previous reports, that falls into
two main groups [35] and four clades [36]: the H1 and H9 clade in
one group and the H3 and H7 clade in the other group (Fig. 5b).
CR6261 neutralized all H1 clade and H9 clade viruses, except for
one of the H2N2 isolates, and potency among subtypes was
relatively well conserved (Fig. 5c) consistent with affinity measure-
ments (Table 3). CR6323 also neutralised the same strains as
CR6261 but 10 fold variability in subtype neutralizing activity was
measured that contrasts with its equivalent affinity for H1, H5 and
H9 subtypes (Fig. 5c). CR6323 binds a different epitope than
CR6261 (Fig. 3b) but in the same antigenic region (Table 2)
suggesting that subtype differences in the presentation of this
epitope impact on functional activity. Consistent with binding data,
none of the tested strains from the H3 or H7 clade were neutralized
by the mAbs (Fig. 5c) including CR6261 for which weak but
consistent ELISA reactivity was measured against rH7 HA. Based
on this analysis the antigenic region recognized by CR6261 and
CR6323 appears to segregate with a previously characterized
division of HA’s that contains, H1, H2, H5, H6, H8, H9, H11, H12,
H13 and H16 subtypes [36].
Identification of the HA binding region for the
heterosubtypic neutralizing mAbs
Conserved structural correlates have been identified that
support the classification of HA subtypes into groups and clades
as described above [37]. These structural features are predomi-
nantly located in the more conserved HA2 fusion subdomain. This
region undergoes a dramatic structural rearrangement between
the neutral (native) and low pH (fusion) forms of HA [38]. Not
surprisingly binding of CR6261 to surface exposed H5 rHA was
lost when subjected to low pH treatment, yet remarkably the
epitopes of both CR6323 and CR6307 were conserved under
these conditions (Fig. 6a). The only significant solvent exposed
region in the HA2 subunit not rearranged during this conforma-
tional shift is the helix 38–55 (region A) [38] which may form part
of the antigenic region recognized by CR6307 and the cross-
neutralizing mAbs (CR6323 and CR6261).
We next investigated the interaction of CR6261 with the helix
38–55 region by modelling. A 3-D structure of the VH-VL region
of CR6261 was modelled by homology to framework regions and
CDR fragments from existing x-ray crystal structures (Fig. 6b). A
striking feature of the subtype cross-reactive mAbs was their
restriction to the VH gene IGHV1-69 (Table 2) which exposes
conserved hydrophobic residues at the tip of the HCDR2 loop, in
particular a phenylalanine at position 54 (Fig. 2; Fig. 6b). Selective
IGHV1-69 germline restriction has been observed for mAbs
binding defined epitopes of gp120 [39] and gp41 [40] from HIV-1
virus and the analysis of the co-crystal of one, D5 and its target an
a-helix in the gp41 inner-core trimer (2CMR), has shown that
these hydrophobic residues are required to stabilize binding [40].
Using the structure 2CMR as a guide, the CR6261 model was
docked in the region of helix 38–55. From this initial position a
concave hydrophobic patch formed by the residues Ile45, Ile48,
Thr49, Val52 and Ile56 of HA2 and His38 and Val40 of HA1 (H3
numbering throughout paper) was identified that could accom-
modate the hydrophobic residues of HCDR2 (Fig. 6c) and in
particular Phe54 (Fig. 6d). Consistent with the binding and
neutralizing properties of CR6261 and the structural classification
of HA subtypes [37] the identified hydrophobic patch is conserved
in x-ray crystal structures of the H1 and H9 group but not in the
H3 and H7 group (Fig. 7).
Confirmation of the stem domain hydrophobic pocket as
the binding region of the heterosubtypic neutralizing
mAbs
Several pieces of experimental evidence support the localisation
of the antigenic region. First, CR6261 neutralisation escape
variants of RG-A/Indonesia/5/05 were generated, after extensive
passaging, that harboured a fixed mutation (H111L) in the HA2
subunit; viruses with this unique mutation were confirmed to be
resistant to CR6261 neutralisation (IC50.100 mg/ml vs. 6.25 mg/
ml for wild type). His111 is a conserved H1 and H9 group specific
residue [37] but is buried in the prefusion state and so not
accessible to direct antibody interaction. Comparison of an H5
structure (Fig. 8a) to an H3 structure where threorine is in position
111 of HA2 (Fig. 8b) shows that when hydrogen bonding is lost
between the His111 side chain and the Thr318 main chain
(Fig. 8a,b; circle) as would occur with the H111L escape mutation
(because Leu111 like Thr111 cannot form a hydrogen bond with
Thr318), the peptidic plane of Thr318 is re-orientated introducing
an exposed carbonyl moiety into the binding pocket (Fig. 8b;
arrow). We predict that the hydration of the carbonyl will modify
the hydrophobic character of the pocket explaining the loss of
CR6261 neutralizing activity.
Second, when H5 residues were substituted for corresponding
H3 residues in the hydrophobic pocket reductions in surface
expressed H5 rHA binding were measured for CR6261 and
CR6323 (Fig. 9a). This was particularly true of the double
mutation H38N and Q40T (HA1) which introduces a glycosyl-
ation site in the pocket. Binding reductions were also seen for the
two H5 to H2 mutants, L320P (HA1) and I45F (HA2), which
Figure 8. Generation of CR6261 neutralisation escape variants.
(a) The hydrogen bond interaction of HA2 His111 with HA1 Thr318 is
shown (circled red) in the H5 structure 2IBX. (b) An H3 structure (1MQM)
is shown where the peptidic plane re-orientation of Thr318 is indicated
by a red arrow.
doi:10.1371/journal.pone.0003942.g008
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introduced residues in the hydrophobic pocket unique to the non-
neutralised human H2N2 strain (Fig. S1) but not for the H5 to H2
mutation A130V (HA2) which is outside the antigenic region;
similarly the H5 to H3 mutation D57N (HA2) which is adjacent to
the hydrophobic pocket did not affect binding (Fig. 9a). None of
the mutations introduced into the hydrophobic pocket completely
blocked binding of CR6261 or CR6323, however the 60%
binding reduction measured for the neutralisation escape mutation
H111L (HA2) suggests that incomplete blocking could still be
functionally relevant (Fig. 9a). This may reflect on one hand the
additive effect of the residues forming the hydrophobic pocket
such that a single substitution does not destroy interaction and on
the other hand the contribution provided by HCDR3 and the
other CDR loops. In this regard the HA2 mutation S54R is
outside the hydrophobic pocket but has a substantial impact on
binding (Fig. 9a).
Although our data argue that the IGHV1-69 CDR2 of CR6261
and the other mAbs has a critical role in forming the antigen
binding site, this VH gene does not confer HA specificity by itself.
A VH gene matched control antibody binding rabies virus
glycoprotein failed to bind or neutralise H5N1 viruses (Table 2)
and no H5 rHA reactivity was measured with a panel of eight
West Nile virus envelope specific mAbs that use the IGHV1-69
gene (data not shown). Rather the proposed role of the
hydrophobic residues on the tip of the HCDR2 loop is in
anchoring HCDR3 and other CDR loops and perhaps orientating
their spatial interaction [39]. Consistent with this, substitution of
Phe54 at the tip of the HCDR2 loop of CR6261 with leucine or
Figure 9. Binding of CR6261 to H5 HA point mutants. (a) FACS binding of IgG1 to surface expressed mutants of H5 rHA. Mean fluorescent
intensity (MFI) values were normalised by NIBRG-14 antiserum reactivity to the corresponding mutant and expressed as the average percentage of
wild type H5 rHA binding from two independent experiments (see key for colour code). Adjacent are sequence alignments of the corresponding
region, mutated residues are boxed. (b) FACS binding activity to WT or mutant H5 rHA performed as above for CR6261 (solid bars), CR6261 with the
HCDR2 mutation F54L (open bars) or F54A (striped bars). MFI was normalised as above and expressed as mean6s.e.m. arbitrary units from two
independent experiments.
doi:10.1371/journal.pone.0003942.g009
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alanine reduced binding in relation to hydrophobicity, and
additive decreases in binding were observed when CR6261
mutants and HA mutants were combined (Fig. 9b).
Finally we observed that CR6307, which does not use the
IGHV1-69 germline gene, is not subtype cross-reactive and only
weakly competes with CR6261 or CR6323 for binding to rHA,
does not appear to be sensitive to the mutations around the
hydrophobic pocket (Fig. 9a), however the mutation S54R
influences its binding suggesting like the fusion shift data (Fig. 6a)
that its epitope is also located in the 38–55 helix region.
In vivo activity of heterosubtypic neutralizing mAb
CR6261 against H5N1 and H1N1 viruses
We examined the in vivo potency of CR6261 in murine lethal
challenge models. Prophylactic administration of CR6261 (5 mg/
kg; i.p.) was 100% protective in a dose titration against 10 LD50
A/Vietnam/1194/04; none of the CR6261 treated mice showed
signs of infection, in contrast all mice that received isotype control
mAb (15 mg/kg; i.p.) suffered from respiratory symptoms by day 4
and succumbed to infection or were sacrificed by day 8 (Fig. 10a).
Similarly, CR6261 fully protected mice against 25 LD50 of the
mouse adapted H1N1 strain A/WSN/33 at 2 mg/kg (Fig. 10b)
thus demonstrating cross-protection. Administration of CR6261
(15 mg/kg; i.p.) to mice (n = 10) one day after infection (i.n.) with
25 LD50 of A/Hong Kong/156/97 or A/WSN/33 fully protected
all animals. Lung pathology in H5N1 infected mice (n = 3) six days
post-infection showed signs only of mild lymphohistiocytic cell
extravasation in CR6261 treated mice (Fig. 10c) while evidence of
bronchiolitis and moderate to severe pneumonia was recorded in
all controls (Fig. 10d).
Clinical interventions to treat H5N1 infections generally begin
after the onset of symptoms. To establish the effective treatment
window of CR6261 a single dose (15 mg/kg) was injected i.v. to
rapidly achieve peak circulating concentrations, 3, 4, 5 or 6 days
after challenge with 25 LD50 A/Hong Kong/156/97 (Fig. 10e). A
rapid reversal of mean weight loss and clinical signs of infection
was measured when CR6261 was given three days or four days
post challenge, time points at which mice had lost 10% and 15%
of body weight respectively; all mice in these treatment groups
regained their full body weight by the end of the observation
period. Remarkably, CR6261 treatment at day five post-infection,
when all mice displayed signs of respiratory distress, was still able
to protect 50% of mice (Fig. 10e, grey box). Our observations with
CR6261 in murine lethal challenge models extend the findings of
others [14,41] and are consistent with the proposal that
intervention with influenza virus neutralizing mAbs may have
clinical utility in human H5N1 cases.
Discussion
In this study we have built combinatorial libraries and selected a
panel of human monoclonal antibodies against H5 HA from a
particular compartment of memory B cells that are characterized
by their continued expression of IgM on the surface. Our results
suggest that IgM+ memory B cells express mAbs recognizing T-
dependent antigens at high affinity, and consistent with a hallmark
of memory B cells, all selected H5N1 mAbs contained mutated
VH genes. Memory B cells are also generally defined by their
rapid proliferation and differentiation into antibody secreting
plasma cells on re-exposure to antigen. Yet from this study it is not
clear that the IgM+ memory B cells expressing the cross-
neutralizing HA specificities participate in a true recall response
upon vaccination. An increase in serum neutralizing activity was
measured in all vaccinated donors for H1N1 but not H5N1, even
in donor #1020 from which the heterosubtypic neutralizing mAbs
were isolated. Thus if the B cell clones expressing CR6261 and the
other cross-reactive mAbs were present in the donor prior to
vaccination (as would be expected) then a true recall response
associated with differentiation into plasma cells has not likely
occurred. Although we can not exclude the possibility that at later
time points serological differences could have been measured the
Figure 10. In vivo protective activity of CR6261 against wild
type H5N1 and H1N1 strains. Kaplan-Meier survival curves of BALB/
c mice were injected (i.p.) with CR6261 or irrelevant control (15 mg/kg)
then challenged 24 h later (i.n.) with (a) 10 LD50 of A/Vietnam/1203/04
(n = 5) or (b) 25 LD50 A/WSN/33 (n = 10) and observed daily for a period
of 21 days. Haematoxylin-Eosin stained lung sections taken 6 d.p.i from
(c) CR6261 or (d) control mAb treated mice (1 d.p.i.) and challenged
with 25 LD50 A/Hong Kong/156/97. (e) Survival (upper panel),
mean6s.e.m. body weight, (middle panel) and median clinical signs
(bottom panel) of mice (n = 10) challenged as in (c,d) and injected i.v.
with 15 mg/kg CR6261 IgG1 3 (dark blue), 4 (light blue), 5 (green) or 6
days (orange) or control mAb (black dotted line) 4 days after challenge
(see colored arrows in bottom panel). The day five time point at which
therapeutic efficacy is lost is indicated by a grey box.
doi:10.1371/journal.pone.0003942.g010
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results are consistent with the observation that measurable
heterosubtypic immunity is rare in the general population [10].
We have not made a comparative analysis of other B cell
compartments to investigate whether related clones are present in
isotype switched memory cells or plasma cells of donor #1020 or
other donors. However, preliminary data for a mAb isolated from
the bone marrow of an H5N1 infected patient was recently
reported that possesses cross-neutralizing activity between H5N1
and H1N1 [13]. Remarkably this mAb uses the IGHV1-69
germline gene and conserves the hydrophobic residues at the tip of
the HCDR2 loop that we show in this study to be critical in
binding the conserved hydrophobic pocket of HA. Unfortunately
without further data it can only be inferred that this mAb is
binding to the same region as CR6261 and other mAbs described
in this study. The ease at which the IgM+ memory B cell repertoire
can be accessed in normal, infected and vaccinated donors
compared to bone marrow and the diversity in this repertoire
compared to antibody secreting cells [16] supports this approach
to generate therapeutic mAbs against other pathogenic targets and
should be further explored.
The epitopes of CR6261, CR6323 and the other cross-
neutralizing mAbs were localised to the stem domain of HA using
a combination of homology modelling, mutagenesis and mapping
with escape variants. This region is highly conserved and, based on
comparisons at a sequence and structural level, appears to
segregate into two groups one containing H1, H2, H5, H6, H8,
H9, H11, H12, H13 and H16 subtypes and the other H3, H4, H7,
H10, H14 and H15 subtypes. The neutralizing mAbs described in
this study recognize antigenic determinants in the first group that
confer different levels of neutralization potency against these
subtypes but do not recognise representative virus strains from
subtypes in the second group tested so far. Escape mutants of a
murine anti-H2N2 mAb (C179) with cross-neutralizing activity to
H1 subtypes but not H3 subtypes have also placed its epitope in
this region [42]. C179 has relatively weak neutralizing and
protective activity against H1 and H5 viruses (e.g. protection from
a lab adapted LPAI H5N2 strain required 70 mg/kg of C179)
[43,44]. Preliminary evidence suggests C179’s mechanism of
action is related to fusion inhibition rather than blocking of
attachment [44]. Although we have not examined the neutralisa-
tion mechanism of the human mAbs identified in this study they,
like C179, do not have hemagglutination inhibition (HAI) activity.
Importantly, we show that mAbs like CR6261 targeting this region
can have potent prophylactic and therapeutic activity and that
humans are capable of generating antibodies directed to this
region. Vaccines with broad heterosubtypic protective activity are
being actively pursued, particularly against matrix protein 2 (M2)
[45–47], however many uncertainties remain about their effec-
tiveness [10]. Vaccination studies have been performed with the
HA2 subunit but have not demonstrated robust protective
responses in experimental models [32,48]. The information
provided here on the conserved antigenic site in the HA stem
domain could provide a new avenue for targeted vaccine
strategies.
Development of clinical interventions against a potential
influenza pandemic are challenged by uncertainty over future
pandemic viral subtypes [1,3,5,49], antigenic variability within
subtypes and the potential for antiviral resistance to emerge [7,8],
as recently observed in H1N1 strains [9]. The mAb CR6261
identified in this study potentially addresses these issues. First, it
neutralises most of the virus subtypes that currently show
pandemic potential (i.e. H2, H5, H6 and H9 viruses). Second, it
was demonstrated to neutralise all five H5N1 virus clades and
subclades tested, which represent viruses isolated from 1997 to
2006. The generation of CR6261 neutralisation escape variants
required extensive viral passaging suggesting that alteration of its
epitope is not easily accomplished without negatively influencing
virus infectivity. The prophylactic and therapeutic utility of
CR6261 against different H5N1 strains and influenza A subtypes
argue for its development as an important alternative or adjunct to
currently stockpiled pandemic interventions.
Supporting Information
Figure S1 Alignment of H2N2 HA sequences. (a) Amino acid
alignment of sequences from CR6261 and CR6323 neutralised
and non-neutralised influenza strains. Only residues that differ
from the top sequence Human H2N2 (Hu_H2; A/Singapore/1/
57) are shown, H3 numbering is used. Other sequences were
Avian H2 (Av_H2; A/WF/Hong Kong/MPU3156/05), Human
H5N1 (Hu_H5; A/Vietnam/1203/04), Avian H5N1 (Av_H5; A/
Japanese white eye/Hong Kong/1038/06), Human H1N1
(Hu_H1; A/Hong Kong/54/98) and Avian H9N2 (Av_H9; A/
Duck/Y280/97). Antigenic sites based on H1 are boxed Ca1 (red),
Ca2 (burgundy), Cb (green), Sa (light blue) and Sb (yellow).
Human H2N2 residues that fall outside the predicted antigenic
sites and differ from the CR6261 neutralised avian H2N2 strain
are boxed on the top sequence. (b) the antigenic sites from above
are shown mapped onto a surface representation of H1N1 crystal
structure (1RUZ) using the colour scheme above, the boxed
unique residues of the non-neutralised human H2N2 strain are
marked in dark blue on the surface.
Found at: doi:10.1371/journal.pone.0003942.s001 (0.08 MB
DOC)
Acknowledgments
We thank Carla Ophorst, Cynthia Leung, Els de Boer-Luitze, Erwin
Claassen, Simon Riemersma, Gerrit Jan Weverling, Marion Cornelissen,
Tonja van der Kuyl, Anna Arov and Herbert Heyneker for advice,
assistance and reagents.
Author Contributions
Conceived and designed the experiments: MT EvdB LLMP LC JtM RC
JSMP JdK. Performed the experiments: EvdB MJ PA AB FC EvD.
Analyzed the data: MT EvdB LLMP PA LC AB FC EvD JtM IL JSMP
JdK JG. Contributed reagents/materials/analysis tools: YG JC RC. Wrote
the paper: MT JG.
References
1. Peiris JSM, de Jong MD, Guan Y (2007) Avian Influenza Virus (H5N1): a
Threat to Human Health. Clin Microbiol Rev 20: 243–267.
2. WHO (2008) Cumulative Number of Confirmed Human Cases of Avian
Influenza A/(H5N1) Reported to WHO. http://www.who.int/csr/disease/
avian_influenza/country/cases_table_2008_06_19/en/index.html.
3. Chin PS, Hoffmann E, Webby R, Webster RG, Guan Y, et al. (2002) Molecular
evolution of H6 influenza viruses from poultry in Southeastern China:
prevalence of H6N1 influenza viruses possessing seven A/Hong Kong/156/97
(H5N1)-like genes in poultry. J Virol 76: 507–516.
4. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, et al. (1999) Human infection
with influenza H9N2. Lancet 354: 916–917.
5. Ma W, Vincent AL, Gramer MR, Brockwell CB, Lager KM, et al. (2007)
Identification of H2N3 influenza A viruses from swine in the United States. Proc
Natl Acad Sci U S A 104: 20949–20954.
6. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, et
al. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis
and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A
101: 1356–1361.
Cross-Neutralizing Flu mAbs
PLoS ONE | www.plosone.org 14 December 2008 | Volume 3 | Issue 12 | e3942
7. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005)
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
N Engl J Med 353: 2667–2672.
8. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of
oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:
1258–1261.
9. WHO/ECDC (2008) Frequently asked questions for Oseltamivir Resistance.
http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html.
10. Subbarao K, Murphy BR, Fauci AS (2006) Development of effective vaccines
against pandemic influenza. Immunity 24: 5–9.
11. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis:
convalescent blood products for Spanish influenza pneumonia: a future H5N1
treatment? Ann Intern Med 145: 599–609.
12. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for
influenza A (H5N1) infection. N Engl J Med 357: 1450–1451.
13. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008)
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian
influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A
105: 5986–5991.
14. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007)
Prophylactic and therapeutic efficacy of human monoclonal antibodies against
H5N1 influenza. PLoS Med 4: e178.
15. Wang ML, Skehel JJ, Wiley DC (1986) Comparative analyses of the specificities
of anti-influenza hemagglutinin antibodies in human sera. J Virol 57: 124–128.
16. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. (2008) Rapid
cloning of high-affinity human monoclonal antibodies against influenza virus.
Nature 453: 667–671.
17. Gerhard W, Yewdell J, Frankel ME, Webster R (1981) Antigenic structure of
influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290:
713–717.
18. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic
structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell
31: 417–427.
19. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, et al. (2003)
Human immunoglobulin M memory B cells controlling Streptococcus
pneumoniae infections are generated in the spleen. J Exp Med 197: 939–945.
20. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, et al. (2004) Human
blood IgM ‘‘memory’’ B cells are circulating splenic marginal zone B cells
harboring a prediversified immunoglobulin repertoire. Blood 104: 3647–3654.
21. Tangye SG, Good KL (2007) Human IgM+CD27+ B cells: memory B cells or
‘‘memory’’ B cells? J Immunol 179: 13–19.
22. Harada Y, Muramatsu M, Shibata T, Honjo T, Kuroda K (2003) Unmutated
Immunoglobulin M Can Protect Mice from Death by Influenza Virus Infection.
J Exp Med 197: 1779–1785.
23. Jayasekera JP, Moseman EA, Carroll MC (2007) Natural Antibody and
Complement Mediate Neutralization of Influenza Virus in the Absence of Prior
Immunity. J Virol 81: 3487–3494.
24. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, et al. (2000)
B-1 and B-2 Cell-derived Immunoglobulin M Antibodies Are Nonredundant
Components of the Protective Response to Influenza Virus Infection. J Exp Med
192: 271–280.
25. CDC (1997) Isolation of avian influenza A(H5N1) viruses from humans–Hong
Kong, May-December 1997. MMWR Morb Mortal Wkly Rep 46: 1204–1207.
26. Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, et
al. (2005) The human antibody repertoire specific for rabies virus glycoprotein as
selected from immune libraries. Eur J Immunol 35: 2131–2145.
27. Kramer RA, Cox F, van der Horst M, van der Oudenrijn S, Res PC, et al.
(2003) A novel helper phage that improves phage display selection efficiency by
preventing the amplification of phages without recombinant protein. Nucleic
Acids Res 31: e59.
28. Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA, et al. (2000)
Functional human monoclonal antibodies of all isotypes constructed from phage
display library-derived single-chain Fv antibody fragments. Journal of Immu-
nological Methods 239: 153–166.
29. Desmet J, Spriet J, Lasters I (2002) Fast and accurate side-chain topology and
energy refinement (FASTER) as a new method for protein structure
optimization. Proteins 48: 31–43.
30. Gerhard W (2001) The role of the antibody response in influenza virus infection.
Curr Top Microbiol Immunol 260: 171–190.
31. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus
entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531–569.
32. Graves PN, Schulman JL, Young JF, Palese P (1983) Preparation of influenza
virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of
cross-reactive HA2 determinants. Virology 126: 106–116.
33. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005)
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1
antibodies. Science 308: 1906–1908.
34. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005)
Characterization of a novel influenza A virus hemagglutinin subtype (H16)
obtained from black-headed gulls. J Virol 79: 2814–2822.
35. Air GM (1981) Sequence relationships among the hemagglutinin genes of 12
subtypes of influenza A virus. Proc Natl Acad Sci U S A 78: 7639–7643.
36. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, et al. (1991) Comparison
of complete amino acid sequences and receptor-binding properties among 13
serotypes of hemagglutinins of influenza A viruses. Virology 182: 475–485.
37. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, et al. (2004) H1 and H7
influenza haemagglutinin structures extend a structural classification of
haemagglutinin subtypes. Virology 325: 287–296.
38. Bullough PA, Hughson FM, Skehel JJ, Wiley DC (1994) Structure of influenza
haemagglutinin at the pH of membrane fusion. Nature 371: 37–43.
39. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, et al. (2004) Structural
basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the
HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A 101:
2706–2711.
40. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, et al. (2006)
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed
antibody. Nat Struct Mol Biol 13: 740–747.
41. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive
immunoprophylaxis and therapy with humanized monoclonal antibody specific
for influenza A H5 hemagglutinin in mice. Respir Res 7: 126.
42. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope
conserved between the hemagglutinins of influenza A virus H1 and H2 strains.
J Virol 67: 2552–2558.
43. Smirnov YA, Lipatov AS, Gitelman AK, Claas EC, Osterhaus AD (2000)
Prevention and treatment of bronchopneumonia in mice caused by mouse-
adapted variant of avian H5N2 influenza A virus using monoclonal antibody
against conserved epitope in the HA stem region. Arch Virol 145: 1733–1741.
44. Okuno Y, Matsumoto K, Isegawa Y, Ueda S (1994) Protection against the
mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal
antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68:
517–520.
45. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A
universal influenza A vaccine based on the extracellular domain of the M2
protein. Nat Med 5: 1157–1163.
46. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent
immunogenicity and efficacy of a universal influenza vaccine candidate
comprising a recombinant fusion protein linking influenza M2e to the TLR5
ligand flagellin. Vaccine 26: 201–214.
47. Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, et al. (2008)
CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine
26: 1243–1252.
48. Gocnik M, Fislova T, Mucha V, Sladkova T, Russ G, et al. (2008) Antibodies
induced by the HA2 glycopolypeptide of influenza virus haemagglutinin
improve recovery from influenza A virus infection. J Gen Virol 89: 958–967.
49. Xu KM, Smith GJ, Bahl J, Duan L, Tai H, et al. (2007) The genesis and
evolution of H9N2 influenza viruses in poultry from southern China, 2000 to
2005. J Virol 81: 10389–10401.
Cross-Neutralizing Flu mAbs
PLoS ONE | www.plosone.org 15 December 2008 | Volume 3 | Issue 12 | e3942
